View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
June 14, 2019

Lumosa to assess stroke drug in Phase II clinical trial

Taiwan-based Lumosa Therapeutics is set to launch a Phase II proof of concept clinical trial to evaluate its drug candidate LT3001 in patients with acute ischemic stroke (AIS).

Taiwan-based Lumosa Therapeutics is set to launch a Phase II proof of concept clinical trial to evaluate its drug candidate LT3001 in patients with acute ischemic stroke (AIS).

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

The company submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) and did not receive any objections during the 30-day reviewing period.

Lumosa is currently seeking global partners to co-develop this project.

LT3001 is a small molecule that demonstrated functions to restore cerebral blood flow and minimise ischemic / reperfusion injury in animal models.

The compound’s safety, tolerability and pharmacokinetic profiles have been validated in a 16-subject Phase I study.

When a single-dose escalation was given intravenously, LT3001 was observed to be well-tolerated without any adverse events. One volunteer in the high-dose arm reported having a mild headache.

Dose selection for the Phase II trial will be based on the finding that LT3001’s blood concentration in low-dose subjects is higher than the effective dose determined in animal studies.

Lumosa intends to initiate the new study in the US by the third quarter or fourth quarter of this year, following the approved protocol.

In order to accelerate recruitment, the company also plans to enrol patients in Taiwan. Lumosa will file an IND application to Taiwan FDA in the near future.

Enrolment in Taiwan is scheduled to begin next year.

Lumosa Therapeutics president and CEO Rong-Chin Lin said: “LT3001’s progression into Phase II clinical trial is a significant milestone in Taiwan’s new drug development history. Judging from the results of the completed studies, LT3001 has the great potential to overcome the above-mentioned obstacles.

“Lumosa will actively seek co-development partners for LT3001 in the world to share development risks, and soon materialise LT3001’s intellectual value.”

Patient enrolment into the Phase II trial is expected to be completed in two years.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena